Biomol Ther.  2020 Jan;28(1):1-17. 10.4062/biomolther.2019.069.

Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells

• Lim J
• Lee A
• Lee HG
• Lim JS

• KMID: 2507817
• DOI: http://doi.org/10.4062/biomolther.2019.069

Abstract

Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that exert suppressive function on the immune response. MDSCs expand in tumor-bearing hosts or in the tumor microenvironment and suppress T cell responses via various mechanisms, whereas a reduction in their activities has been observed in autoimmune diseases or infections. It has been reported that the symptoms of various diseases, including malignant tumors, can be alleviated by targeting MDSCs. Moreover, MDSCs can contribute to patient resistance to therapy using immune checkpoint inhibitors. In line with these therapeutic approaches, diverse oligonucleotide-based molecules and small molecules have been evaluated for their therapeutic efficacy in several disease models via the modulation of MDSC activity. In the current review, MDSC-targeting oligonucleotides and small molecules are briefly summarized, and we highlight the immunomodulatory effects on MDSCs in a variety of disease models and the application of MDSC-targeting molecules for immuno-oncologic therapy.

Keyword

Myeloid-derived suppressor cells (MDSCs); Oligonucleotide-based molecules; Small molecules; Tumor microenvironment; Immune suppression; MDSC-targeting agents